Immunophenotypic signature of primary glioblastoma multiforme: A case of extended progression free survival

doi:10.12998/wjcc.v5.i6.247

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 5, Issue 6

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (5882)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-3) series, Tables (1-2) series.

Item

Count

PDF

345

WORD

290

HTML

2610

Figures (1-3)

210

Tables (1-2)

199

Sum=3654

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

863

Download

1365

Sum=2228

Jun 16, 2017 (publication date) through Jul 26, 2024

Times Cited of This Article

Times Cited (8)

Journal Information of This Article

Publication Name

World Journal of Clinical Cases

ISSN

2307-8960

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Case Report

World J Clin Cases. Jun 16, 2017; 5(6): 247-253
Published online Jun 16, 2017. doi: 10.12998/wjcc.v5.i6.247

Table 2 Parameters evaluated in circulation (serum/plasma)

No.	Case/group	NLR	hTERT	YKL-40	TIMP-1	¹IL-6	²HMGA1
1	Case	3.9	6.125	71.47	80	645.207	16.8
2	Control (n = 15)	1.6 (0.87-28)	1.14 (0.22-1.585)	18.3 (1.12-66.7)	23.7 (10.3-88.4)	48.9 (6.71-72.8)	-
3	GBM (n = 30)	5.58 (3.1-18)	2.18 (0.565-8.84)	101.2 (21.2-198.8)	93.8 (37.2-185.1)	197.6 (59.2-803.7)	30.613

¹n = 15; hTERT, TIMP-1 and YKL-40, IL-6 quantified in ng/L, ng/mL and pg/mL respectively;

²HMGA1 quantified in terms of protein band density. NLR: Neutrophil lymphocyte ratio; HMGA1: High mobility group-A1; hTERT: Human telomerase reverse transcriptase; IL-6: Interleukin-6; TIMP-1: Tissue inhibitor of metalloproteinases-1; YKL-40: Human chitinase-3-like-protein-1.

Citation: Gandhi P, Khare R, Garg N, Sorte S. Immunophenotypic signature of primary glioblastoma multiforme: A case of extended progression free survival. World J Clin Cases 2017; 5(6): 247-253
URL: https://www.wjgnet.com/2307-8960/full/v5/i6/247.htm
DOI: https://dx.doi.org/10.12998/wjcc.v5.i6.247